drugset / Trial / NCT04767087

Honey and Nigella Sativa in COVID-19 Prophylaxis

NCT04767087

Phase 2/3 Unknown 1000 enrolled Sohaib Ashraf
RandomizedParallel-groupTriple-blindPrevention

Summary

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Timeline

Start
2021-03-05
Primary completion
2022-02-15
Completion
2022-04-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Honey Unknown 0.5 g/kg
Comparator Nigella sativa seed Traditional medicine (herbal / TCM) 40 mg/kg

Indications